Dr. Koithara Varkey Thomas, M.D.
Nephrology (Kidney) (Nephrology Physician)
Eastern Nephrology Associates, 277 Memorial Drive
Jacksonville, NC 28546
Who else practices at this address →
Onslow County is a federal primary care and mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 586
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
NC license 200300295
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Health Care Wayne Goldsboro, NC
- Onslow Memorial Hospital Jacksonville, NC
- Unc Lenoir Health Care Kinston, NC
- Sampson Regional Medical Center Clinton, NC
Medical groups
- Eastern Nephrology Associates PLLC (77 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 586
- Services billed
- 4,919
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 840 | 17 |
| Insertion of needle into vein for collection of blood sample | 640 | 377 |
| Established patient office or other outpatient visit, 30-39 minutes | 508 | 356 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 470 | 314 |
| Kidney function blood test panel | 348 | 236 |
| Creatinine level to test for kidney function or muscle injury | 329 | 228 |
| Parathormone (parathyroid hormone) level | 328 | 232 |
| Automated urinalysis test | 303 | 239 |
| Magnesium level | 235 | 168 |
| Vitamin d-3 level | 212 | 181 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in Jacksonville, NC | 136 |
| Calcitriol Other prescribers in Jacksonville, NC | 99 |
| Carvedilol Other prescribers in Jacksonville, NC | 76 |
| Lisinopril Other prescribers in Jacksonville, NC | 75 |
| Amlodipine Besylate Other prescribers in Jacksonville, NC | 73 |
| Losartan Potassium Other prescribers in Jacksonville, NC | 58 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Jacksonville, NC | 51 |
| Jardiance (empagliflozin) Other prescribers in Jacksonville, NC | 50 |
| Clonidine Hcl Other prescribers in Jacksonville, NC | 49 |
| Allopurinol Other prescribers in Jacksonville, NC | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 28 payments worth $542 in total to this clinician.
| Travere Therapeutics, Inc. | $77.69 |
|---|---|
| Amgen Inc. | $75.42 |
| Calliditas Therapeutics US Inc. | $75.00 |
| Ardelyx, Inc. | $71.22 |
| Akebia Therapeutics Inc | $71.16 |
| Otsuka America Pharmaceutical, Inc. | $66.05 |
| Novartis Pharmaceuticals Corporation | $40.45 |
| Bayer HealthCare Pharmaceuticals Inc. | $24.99 |
| Food and Beverage | $535 |
|---|---|
| Education | $7.47 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Nov 19, 2025 | Education Filspari · Kidney Disease · in-kind | $4.15 |
| Travere Therapeutics, Inc. Oct 15, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Oct 23, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $457,024 in research payments for these studies, mostly to the institutions running them.
- A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APP…
AstraZeneca UK Limited - A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
Vertex Pharmaceuticals Incorporated - Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
Eli Lilly and Company · Withdrawn · NCT06598631 - A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.